At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 224 enrolled
Drug / intervention
botulinum toxin type A +1 morebiological
Likely dose
botulinum toxin type A 20 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
In Brief
A Phase 4 clinical trial evaluating botulinum toxin type A for Glabellar Lines. Completed, enrolled 224 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of two different types of botulinum toxin type A for the treatment of glabellar frown lines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Lines
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
Primary CompletionJan 2011
First PostedJan 2011
Study CompletionApr 2011
TodayJul 2026
First PostedJan 6, 2011
Enrollment StartSep 1, 2010
Primary CompletionJan 1, 2011
Study CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.5 years ago
Interventions
botulinum toxin type Abiological
20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
botulinum toxin type Abiological
30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0